/CLCS
CLCS Stock - Cell Source, Inc.
Healthcare|BiotechnologyOTC
$0.50+0.00%
+$0.00 (+0.00%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.55
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLCS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.49 – $0.51
TARGET (TP)$0.57
STOP LOSS$0.46
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-157.98
52W High$0.75
52W Low$0.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,848,500 | $-4,325,000 | $-4,175,000 | $-4,019,000 | $-3,638,000 |
| Net Income | $-4,771,046 | $-5,321,000 | $-5,168,000 | $-5,472,000 | $-4,560,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.15 | $-0.17 | $-0.18 | $-0.19 | $-0.19 |
Company Overview
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CLCSBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.03
Q4 2024
EPS Surprise History
Q3 23
No data
Q3 23
No data
Q3 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | — | — | — |
Q3 2025 | Aug 1, 2025 | — | — | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.03 | — | — |
Q3 2024 | Aug 19, 2024 | — | $-0.04 | — | — |
Q3 2024 | Jul 29, 2024 | — | $-0.03 | — | — |
Q2 2024 | Jun 24, 2024 | — | $-0.03 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.04 | — | — |
Q3 2023 | Sep 19, 2023 | — | $-0.03 | — | — |
Q3 2023 | Aug 23, 2023 | — | $-0.05 | — | — |
Q3 2023 | Aug 8, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 8, 2022 | — | $-0.04 | — | — |
Q4 2022 | Dec 2, 2022 | — | $-0.04 | — | — |
Q4 2022 | Nov 2, 2022 | — | $-0.04 | — | — |
Q2 2022 | Apr 15, 2022 | — | $-0.03 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.05 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.04 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.05 | — | — |
Q2 2021 | Apr 15, 2021 | — | $-0.04 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-0.04 | — | — |
Q3 2020 | Aug 14, 2020 | — | $-0.04 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CLCS
What is CLCS's current stock price?
Cell Source, Inc. (CLCS) is currently trading at $0.50 per share. The stock has moved +0.00% today.
What is the analyst price target for CLCS?
No analyst price targets are currently available for this stock.
What sector is Cell Source, Inc. in?
Cell Source, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CLCS's market cap?
Cell Source, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does CLCS pay dividends?
No, Cell Source, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACMSY
AccuStem Sciences Limited
$0.13
0GLABF
Gemina Laboratories Ltd.
$0.09
Mkt Cap: $0.0B
HMTXF
Hemostemix Inc.
$0.06
Mkt Cap: $0.0B
HSITF
Hadasit Bio-Holdings Ltd
$0.12
Mkt Cap: $0.0B
PPCB
Propanc Biopharma, Inc.
$0.71
Mkt Cap: $0.0B
QPTFF
Quest PharmaTech Inc.
$0.01
Mkt Cap: $0.0B
SRBCF
Sirona Biochem Corp.
$0.01
Mkt Cap: $0.0B
SYGGF
Synairgen plc
$0.00
Mkt Cap: $0.0B
TELIF
Telescope Innovations Corp.
$0.25
Mkt Cap: $0.0B
ZHCLF
Zenith Capital Corp.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to CLCS for comparison